Stephanie Baum

June 29, 2026 by The Education University of Hong Kong edited by Stephanie Baum , reviewed by Robert Egan

Zelis CEO Amanda Eisel discussed how AI can create value when it is applied to measurable outcomes: simplifying claims workflows, reducing administrative burden, strengthening payment integrity, improving the payments experience, and empowering members to navigate their healthcare financial journey with confidence.

Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed some of the takeaways from UnitedHealth Group's press event, transparency, and pharma company Lilly's efforts to hold hospitals accountable in 340B drug discount program.

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

A webinar by Verato and MedCity News on July 22 will explore how building a trusted data foundation that connects the healthcare ecosystem can improve how payers deploy AI.

A webinar, sponsored by Verato, offered a robust discussion with executives from Providence, Yale New Haven Health System and Verato on navigating an increasingly complex landscape of sharing electronic patient data.

On July 22, a webinar sponsored by Verato will spotlight perspectives of executives from Scan Health Plan and the Alliance of Community Health Plans.

A five minute survey from MedCity News asks payers what they think of AI and how it is being implemented. Participate today and we will reward you!

Healh insurers are interested in assessing the potential for AI to improve everything from prior authorization to member management. But data fragmentation poses an enormous challenge to AI readiness in healthcare for both payers and provider health plans. On a recent webinar sponsored by Verato, panelists from SCAN Health Group and the Alliance of Community Health Plans discussed how their organizations are meeting the moment.

Approximately 850 million people globally (9.1% of the world's population) have chronic kidney disease (CKD). The number of affected individuals has grown steadily during the past 20 years and is on track to continue rising. Existing drugs, such as RAAS inhibitors and angiotensin receptor blockers, are commonly prescribed, but their effectiveness varies from patient to patient. Moreover, these drugs can slow disease progression but cannot stop it.